“Our Chimigen vaccine platform is an innovative technology designed to activate a broad immune response against viral infection. HepaVaxx B Vaccine is the first candidate from this platform to enter into clinical studies and represents ‘first in man’ of our recombinant protein technology,” commented Dr Lorne Tyrrell, CEO and chief scientific officer of ViRexx.
In preclinical testing, HepaVaxx B has produced both cellular and humoral immune responses. ViRexx believes that the development of humoral and cellular responses may be effective in clearing the virus from patients with chronic hepatitis B infection.
HepaVaxx B Vaccine consists of a recombinant chimeric molecule containing a hepatitis B viral antigen and a portion of a murine monoclonal antibody. The molecule is designed to target dendritic cells, which play a significant role in antigen presentation and initiation of an immune response.